Abstract:Abstract The purpose of this study was to analyze the association between next-generation sequencing (NGS) genotypic profiles and conventional clinicopathologic characteristics in patients with acute myeloid leukemia (AML) with NPM1 mutation ( NPM1 mut ). We selected 238 NPM1 mut patients with available NGS information on 112 genes related to blood diseases using the χ 2 and Mann-Whitney U tests and a multivariable logistic model to analyze the correlation between genomic alterations and clinicopathologic parameters. Compared with the NPM1 mut / FLT3- ITD (−) group, the NPM1 mut / FLT3- ITD (+) group presented borderline frequent M5 morphology [78/143 (54.5%) vs. 64/95 (67.4%); P = 0.048], higher CD34- and CD7-positive rates (CD34: 20.6% vs. 47.9%, P < 0.001; CD7: 29.9% vs. 61.5%, P < 0.001) and a lack of favorable−/adverse-risk karyotypes (6.4% vs. 0%; P = 0.031). In the entire NPM1 mut cohort, 240 NPM1 mutants were identified, of which 10 (10/240, 4.2%) were missense types. When confining the analysis to the 205 cases with NPM1 mut insertions/deletions-type and normal karyotype, multivariable logistic analysis showed that FLT3- ITD was positively correlated with CD34 and CD7 expressions ( OR = 5.29 [95% CI 2.64–10.60], P < 0.001; OR = 3.47 [95% CI 1.79–6.73], P < 0.001, respectively). Ras-pathway mutations were positively correlated with HLA-DR expression ( OR = 4.05 [95% CI 1.70–9.63], P = 0.002), and KRAS mutations were negatively correlated with MPO expression ( OR = 0.18 [95% CI 0.05–0.62], P = 0.007). DNMT3A -R882 was positively correlated with CD7 and HLA-DR expressions ( OR = 3.59 [95% CI 1.80–7.16], P < 0.001; OR = 13.41 [95% CI 4.56–39.45], P < 0.001, respectively). DNMT3A mutation was negatively correlated with MPO expression ( OR = 0.35 [95% CI 1.48–8.38], P = 0.004). TET2 / IDH1 mutations were negatively correlated with CD34 and CD7 expressions ( OR = 0.26 [95% CI 0.11–0.62], P = 0.002; OR = 0.30 [95% CI 0.14–0.62], P = 0.001, respectively) and positively correlated with MPO expression ( OR = 3.52 [95% CI 1.48–8.38], P = 0.004). In conclusion, NPM1 mut coexisting mutations in signaling pathways ( FLT3- ITD and Ras-signaling pathways) and methylation modifiers ( DNMT3A and TET2 / IDH1 ) are linked with the expressions of CD34, CD7, HLA-DR and MPO, thereby providing a mechanistic explanation for the immunophenotypic heterogeneity of this AML entity.

Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing

Prognostic utility of six mutated genes for older patients with acute myeloid leukemia.

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia

[Mutational Spectrum and Prognosis Analysis of AML Patients Based on High-Throughput Sequencing]

Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients

Mutation Topography and Risk Stratification for De Novo Acute Myeloid Leukaemia with Normal Cytogenetics and No Nucleophosmin 1 (NPM1) Mutation or Fms‐like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3‐ITD)

The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia

Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients

Spectrum and Clinical Features of Gene Mutations in Chinese Pediatric Acute Lymphoblastic Leukemia

Acute Myeloid Leukaemia with Normal Cytogenetics and NPM1-Mutation: Impact of Mutation Topography on Outcomes

Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China

Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5